Crotaline snake bite in the Ecuadorian Amazon: randomised double blind comparative trial of three South American polyspecific antivenoms
- 11 November 2004
- Vol. 329 (7475), 1129
- https://doi.org/10.1136/bmj.329.7475.1129
Abstract
To compare the efficacy and safety of three polyspecific antivenoms for bites by pit vipers.Randomised double blind comparative trial of three antivenoms.Shell, Pastaza, southeastern Ecuador.210 patients with incoagulable blood were recruited from 221 consecutive patients admitted with snake bite between January 1997 and December 2001.One of three antivenoms manufactured in Brazil, Colombia, and Ecuador, chosen for their preclinical potency against Ecuadorian venoms.Permanent restoration of blood coagulability after 6 and 24 hours.The snakes responsible for the bites were identified in 187 cases: 109 patients (58%) were bitten by Bothrops atrox, 68 (36%) by B bilineatus, and 10 (5%) by B taeniatus, B brazili, or Lachesis muta. Eighty seven patients (41%) received Colombian antivenom, 82 (39%) received Brazilian antivenom, but only 41 (20%) received Ecuadorian antivenom because the supply was exhausted. Two patients died, and 10 developed local necrosis. All antivenoms achieved the primary end point of permanently restoring blood coagulability by 6 or 24 hours after the start of treatment in > 40% of patients. Colombian antivenom, however, was the most effective after initial doses of 20 ml (two vials), < 70 ml, and any initial dose at both 6 and 24 hours. An initial dose of 20 ml of Colombian antivenom permanently restored blood coagulability in 64% (46/72) of patients after 6 hours (P = 0.054 compared with the other two antivenoms) and an initial dose of < 70 ml was effective at 6 hours (65%, P = 0.045) and 24 hours (99%, P = 0.06). Early anaphylactoid reactions were common (53%, 73%, and 19%, respectively, for Brazilian, Colombian, and Ecuadorian antivenoms, P < 0.0001) but only three reactions were severe and none was fatal.All three antivenoms can be recommended for the treatment of snakebites in this region, though the reactogenicity of Brazilian and Colombian antivenoms is a cause for concern.This publication has 25 references indexed in Scilit:
- Inflammatory pathogenesis of snake venom metalloproteinase‐induced skin necrosisEuropean Journal of Immunology, 2003
- Clinical indicators of envenoming and serum levels of venom antigens in patients bitten by Bothrops lanceolatus in MartiniqueTransactions of the Royal Society of Tropical Medicine and Hygiene, 1997
- A randomized double-blind clinical trial of two antivenoms in patients bitten by Bothrops atrox in ColombiaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1996
- Pharmacological study of edema induced by venom of the snake Bothrops asper (terciopelo) in miceToxicon, 1995
- Reliability of the simple 20 minute whole blood clotting test (WBCT20) as an indicator of low plasma fibrinogen concentration in patients envenomed by Bothrops snakesToxicon, 1994
- Envenoming by viper bites in France: Clinical gradation and biological quantification by ELISAToxicon, 1992
- Bites by Russell's vipers (Daboia russelii siamensis) in Myanmar: effect of the snake's length and recent feeding on venom antigenaemia and severity of envenomingTransactions of the Royal Society of Tropical Medicine and Hygiene, 1991
- Antivenoms: A list of hyperimmune sera currently available for the treatment of envenoming by bites and stingsToxicon, 1991
- Pharmacological evaluation of rat paw oedema induced byBothrops jararaca venomInflammation Research, 1989
- Prediction, prevention, and mechanism of early (anaphylactic) antivenom reactions in victims of snake bites.BMJ, 1986